603P - A phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)

J Bendell,C Lieu,K.P.S Raghav,G Argilés,A Cubillo,X Qu,Y Yan,M Merchant,H Zeuner,J.D Gallo,N.H Segal

doi:10.1093/annonc/mdz246.080

603P - A phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)

J Bendell, C Lieu + Show 9 more

Open Access

https://doi.org/10.1093/annonc/mdz246.080

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 3	License type: publisher-specific-oa

Affiliation: University of Colorado Denver, The University of Texas MD Anderson Cancer Center, Institut Català d'Oncologia, Memorial Sloan Kettering Cancer Center

#Research Grant #Part-time Employment + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

603P - A phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)

Full Text